AbCellera Biologics (ABCL) Deferred Taxes (2021)

AbCellera Biologics' (ABCL) quarterly Deferred Taxes came in at $1.2 million in Q4 2021, up 131.05% on a QoQ basis from -$4.0 million in Q3 2021.

AbCellera Biologics (ABCL) Deferred Taxes (2021) Analysis & Trends

AbCellera Biologics (ABCL) has 1 years of Deferred Taxes data on file, last reported at $1.2 million in Q4 2021.

Quarterly Deferred Taxes changed N/A year-over-year to $1.2 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was -$2.0 million (changed N/A YoY) and the FY2023 annual result came in at $2.0 million, up 192.72% from the prior year.
Deferred Taxes climbed to $1.2 million in Q4 2021, from -$4.0 million in the prior quarter.
In the past five years, Deferred Taxes ranged from a high of $1.2 million in Q4 2021 to a low of -$4.0 million in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-69.70 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	194.40 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-137,876.64
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	2.66 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	AbCellera Biologics	3.49 Bn	3.49 Bn	-	-

Download Data